Drug Profile
Recombinant erythropoietin - Prolong Pharmaceuticals/Zydus Cadila
Alternative Names: EPEG; PEG-EPO; PEGEPO - Cadila/Prolong; Pegylated erythropoietin - Cadila/Prolong; ZY-7318Latest Information Update: 19 Dec 2021
Price :
$50
*
At a glance
- Originator Prolong Pharmaceuticals; Zydus Cadila
- Class Antianaemics; Polyethylene glycols; Recombinant erythropoietins; Recombinant fusion proteins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anaemia; Beta-thalassaemia
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for phase-I development in Beta-thalassaemia in Thailand (SC, Injection)
- 28 Jan 2020 No recent reports of development identified for phase-I development in Anaemia in India (Parenteral)
- 25 Jan 2018 Recombinant erythropoietin is still in phase I trials for anaemia in India (Zydus pipeline, January 2018)